Treatment outcomes of ranibizumab versus aflibercept for neovascular age-related macular degeneration. data from the fight retinal blindness registry
International Journal of Development Research
Treatment outcomes of ranibizumab versus aflibercept for neovascular age-related macular degeneration. data from the fight retinal blindness registry
Received 17th July, 2020; Received in revised form 29th August, 2020; Accepted 17th September, 2020; Published online 30th October, 2020
Copyright © 2020, Călugăru and Mihai Călugăru. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors are commenting on the study entitled “Treatment outcomes of ranibizumab versus aflibercept for neovascular age-related macular degeneration. Data from the fight retinal blindness registry”, published by Bhandari et al. in Ophthalmology 2020;127(3):369-376, which compared the 3-year treatment outcomes of ranibizumab and aflibercept in 965 treatment-naive eyes with neovascular age-related macular degeneration. The authors of this study found that treatment outcomes of neovascular age-related macular degeneration in routine clinical practice with either ranibizumab or aflibercept were similar at 3 years in terms of visual outcomes, treatment frequency, and visits. We believe that the validation, extrapolation, and generalizability of these findings can be made only by statistical analyses including all the missing baseline potential predictive factors referred to above by us in addition to the baseline characteristics already evaluated in this study, serving to emphasize the key metrics assessing the comparatve efficacy of ranibizumab and aflibercept in neovascular age-related macular degeneration.
